Table 2.
Treatments and outcomes
| COVID-19 treatment | |
| Hydroxychloroquine | 73 (69%) |
| Systemic corticosteroids | 66 (62%) |
| Azithromycin | 60 (57%) |
| Tocilizumab | 51 (48%) |
| Anakinra | 22 (21%) |
| Siltuximab | 5 (5%) |
| Remdesivir | 5 (5%) |
| Respiratory support in RICU | |
| High flow oxygen nasal cannula | 33 (31%) |
| Non-invasive ventilation | 15 (14%) |
| Days since tracheostomy to decannulation (median [IQR]; n = 31) | 25.5 [19–34] |
| Days since admission to decannulation (median [IQR]; n = 31) | 8 [5–12] |
| NIV duration, days (median [IQR]; n = 14) | 4 [1–6.5] |
| HFNC duration, days (median [IQR]; n = 32) | 5 [3–7] |
| Renal replacement therapy | 9 (9%) |
| Vasopressors | 3 (3%) |
| Destination | |
| Discharge to COVID-19 ward | 75 (71%) |
| Transfer to ICU | 17 (16%) |
| Death | 14 (13%) |
| Outcomes | |
| 30-day mortality | 15 (14%) |
| Global mortality at 90 days | 20 (19%) |
| Days since admission to RICU (median [IQR]) | 13 [4–25.3] |
| LOS in RICU (median [IQR]) | 7 [4–11] |
| LOS (median [IQR]) | 34 [17–52] |
| Days since admission to death | 27 [12–34] |
Data is presented as number of patients (%), median [interquartile range]
LOS length of stay (days)